Market Place
Sourcing Support
Enforcement Report - Week of July 6, 2022
06 Jul 2022 //
FDA
AstraZeneca targets Pfizer and Alnylam with Ionis ATTR pact
08 Dec 2021 //
FIERCEPHARMA
Tegsedi® Receives Innovative Drug Category Pricing in Brazil
11 Oct 2021 //
PRNEWSWIRE
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen)
29 Oct 2020 //
PRNEWSWIRE
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen)
22 Jul 2020 //
PRNEWSWIRE
Akcea announces approval for reimbursement of TEGSEDI®inotersen
07 Jun 2020 //
PRNEWSWIRE
Akcea announces approval for reimbursement of TEGSEDI® (inotersen)
01 Jun 2020 //
PRNEWSWIRE
Akcea & Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI®
28 May 2020 //
PHARMIWEB
Akcea Canada Confirms Letter of Intent with Pan-Canadian Alliance for inotersen
13 May 2020 //
NEWSWIRE
Akcea taps first commercial chief as Waylivra debuts and pipeline advances
05 Nov 2019 //
FIERCEP PHARMA
Akcea Therapeutics Appoints Chief Commercial Officer
24 Oct 2019 //
CONTRACT PHARMA
Ionis CBO takes over Akcea as CEO, CBO and COO head out the door
24 Sep 2019 //
FIERCE BIOTECH
SMC rejects Orkambi, accepts four medicines
13 Aug 2019 //
PHARMA TIMES
Alnylam`s Onpattro back in the game against Ionis, thanks to NICE U-turn
09 Jul 2019 //
FIERCE PHARMA
Final NICE guidance issued for Akcea’s Tegsedi
24 May 2019 //
PHARMA TIMES
Akcea`s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR
23 May 2019 //
PHARMAFILE
NICE recommends Akcea`s Tegsedi for rare, life-threatening progressive disease
17 Apr 2019 //
PHARMAFILE
Akcea steals march on Alnylam with NICE approval
17 Apr 2019 //
PMLIVE
NICE flip-flops to back Ionis rare disease treatment Tegsedi
16 Apr 2019 //
FIERCE PHARMA
NICE reject two treatments for fatal, ultra-rare disease
13 Dec 2018 //
PHARMA FILE
Ionis, Akcea get their shot at competing with Alnylam for a rare disease group
09 Oct 2018 //
ENDPTS
Akcea Therapeutics genetic disease treatment gets FDA approval
06 Oct 2018 //
REUTERS
FDA rejects rare disease drug developed by Cambridge`s Akcea
28 Aug 2018 //
BIZ JOURNALS
FDA nixes Akcea’s volanesorsen despite favorable AdComm
28 Aug 2018 //
FIERCE BIOTECH
FDA Gives Thumbs-Down to Rare Disease Drug from Ionis, Akcea
28 Aug 2018 //
XCONOMY
FDA declines to approve Akcea-Ionis genetic disease drug
27 Aug 2018 //
REUTERS
Ionis USA Ltd`s Tegsedi(inotersen sodium) Receives Approval in Europe
07 Aug 2018 //
EMA
Akcea, PTC Therapeutics Collaborate on 2 Rare Disease Drugs in Latin America
02 Aug 2018 //
PR NEWSWIRE
IONIS-HTT Rx (RG6042) Granted PRIME Designation by the EMA
02 Aug 2018 //
PR NEWSWIRE
Ionis Closes Collaboration with Biogen to Develop Drugs for Neurological Dis
05 Jun 2018 //
PR NEWSWIRE
FDA delays decision on inotersen, handing lead to Alnylam
04 May 2018 //
FIERCE BIOTECH
Swapping stock and cash, Ionis turns to closely-controlled Akcea for a deal
15 Mar 2018 //
ENDPTS
